Second chance: new combo aims to clear hepatitis c after relapse
NCT ID NCT07565948
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a 12-week course of three antiviral drugs (sofosbuvir, velpatasvir, and voxilaprevir) in 200 adults with chronic hepatitis C whose virus returned after previous treatment. The main goal is to see if the virus becomes undetectable 12 weeks after therapy ends. Researchers will also monitor liver function and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sofosbuvir/Velpatasvir/Voxilaprevir (a combination of three antiviral drugs)
- What this could lead to
- If successful, this could provide a reliable retreatment option for hepatitis C patients whose virus came back after initial therapy.
- What could go wrong
- This is a mid-stage study with 200 participants, so results may not apply to everyone. Some patients may not respond or may experience side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS C VIRUS (HCV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Xiangya Hospital of Central South University
Changsha, Hunan, 410000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smartphone app and peer mentors boost HIV prevention for people leaving jail?
- Massive review probes hepatitis c pill safety in drug users
- AI tool aims to catch hidden hepatitis c and HIV in ERs
- New All-in-One test could save thousands of babies from infections
- Prison needle programs get a boost to fight HIV and hepatitis c